| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Annals of Surgical Oncology, Vol 3, Issue 5 495-500, Copyright © 1996 by Society of Surgical Oncology
ARTICLES |
D. McAneny, C. A. Ryan, R. M. Beazley and H. L. Kaufman
Department of Surgery, Boston University, Massachusetts, USA.
BACKGROUND: The inadequacy of systemic treatments of advanced colorectal cancer has aroused interest in biologic therapy. Recent animal models have demonstrated the efficacy and safety of a recombinant vaccine that contains vaccinia and the gene for carcinoembryonic antigen (rV-CEA). METHODS: A phase I clinical trial of rV-CEA was conducted to assess vaccine toxicities, the maximum tolerated dosage, resulting immune activities, and tumour responses. A dose-escalation protocol was devised for three concentrations. Six patients per dosage were each to receive three vaccinations. RESULTS: Seventeen patients with advanced colorectal cancer received a total of 44 vaccinations. Mild local and systemic reactions-comparable to those seen with vaccinia alone-were observed and were typically associated with the first vaccination. No significant complications or deaths were caused by the rV-CEA. In particular, no autoimmune colitis developed, nor did leukopenia occur, despite some homology between CEA and leukocyte antigens. All three vaccine concentrations were equally well tolerated. Most patients demonstrated tumor progression by clinical and radiographic parameters and by CEA levels. Immune assays are pending. CONCLUSIONS: This phase I trial demonstrated the safety of rV-CEA in patients with advanced colorectal cancer. Future clinical studies are warranted and will likely be influenced by investigations of the immune responses to the vaccine.
This article has been cited by other articles:
 |
|
 |
|
  D. Nagorsen and E. Thiel Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3064 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dai, T. Wan, B. Wang, X. Zhou, F. Xiu, T. Chen, Y. Wu, and X. Cao More Efficient Induction of HLA-A*0201-Restricted and Carcinoembryonic Antigen (CEA)-Specific CTL Response by Immunization with Exosomes Prepared from Heat-Stressed CEA-Positive Tumor Cells Clin. Cancer Res., October 15, 2005; 11(20): 7554 - 7563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Marshall, J. L. Gulley, P. M. Arlen, P. K. Beetham, K.-Y. Tsang, R. Slack, J. W. Hodge, S. Doren, D. W. Grosenbach, J. Hwang, et al. Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen-Expressing Carcinomas J. Clin. Oncol., February 1, 2005; 23(4): 720 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Kaufman Integrating Bench With Bedside: The Role of Vaccine Therapy in the Treatment of Solid Tumors J. Clin. Oncol., February 1, 2005; 23(4): 659 - 661. [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Mapara and M. Sykes Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Greiner, H. Zeytin, M. R. Anver, and J. Schlom Vaccine-based Therapy Directed against Carcinoembryonic Antigen Demonstrates Antitumor Activity on Spontaneous Intestinal Tumors in the Absence of Autoimmunity Cancer Res., December 1, 2002; 62(23): 6944 - 6951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schmitz, E. Reali, J. W. Hodge, A. Patel, G. Davis, J. Schlom, and J. W. Greiner Identification of an Interferon-{gamma}-inducible Carcinoembryonic Antigen (CEA) CD8+ T-Cell Epitope, Which Mediates Tumor Killing in CEA Transgenic Mice Cancer Res., September 1, 2002; 62(17): 5058 - 5064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dermime, A. Armstrong, R. E Hawkins, and P. L Stern Cancer vaccines and immunotherapy Br. Med. Bull., July 1, 2002; 62(1): 149 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. McCart, J. M. Ward, J. Lee, Y. Hu, H. R. Alexander, S. K. Libutti, B. Moss, and D. L. Bartlett Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes Cancer Res., December 1, 2001; 61(24): 8751 - 8757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. von Mehren, P. Arlen, J. Gulley, A. Rogatko, H. S. Cooper, N. J. Meropol, R. K. Alpaugh, M. Davey, S. McLaughlin, M. T. Beard, et al. The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma Clin. Cancer Res., May 1, 2001; 7(5): 1181 - 1191. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Marshall, R. J. Hoyer, M. A. Toomey, K. Faraguna, P. Chang, E. Richmond, J. E. Pedicano, E. Gehan, R. A. Peck, P. Arlen, et al. Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses J. Clin. Oncol., December 1, 2000; 18(23): 3964 - 3973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. von Mehren, P. Arlen, K. Y. Tsang, A. Rogatko, N. Meropol, H. S. Cooper, M. Davey, S. McLaughlin, J. Schlom, and L. M. Weiner Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas Clin. Cancer Res., June 1, 2000; 6(6): 2219 - 2228. [Abstract] [Full Text]
|
|
|
|
|
|
J. P. Eder, P. W. Kantoff, K. Roper, G. Xu, G. J. Bubley, J. Boyden, L. Gritz, G. Mazzara, W. K. Oh, P. Arlen, et al. A Phase I Trial of a Recombinant Vaccinia Virus Expressing Prostate-specific Antigen in Advanced Prostate Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1632 - 1638. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. F. X. Gnant, L. A. Noll, K. R. Irvine, M. Puhlmann, R. E. Terrill, H. R. Alexander Jr., and D. L. Bartlett Tumor-Specific Gene Delivery Using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases J Natl Cancer Inst, October 20, 1999; 91(20): 1744 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. X. Gnant, A. C. Berger, J. Huang, M. Puhlmann, P. C. Wu, M. J. Merino, D. L. Bartlett, H. Richard Alexander, and S. K. Libutti Sensitization of Tumor Necrosis Factor {{alpha}}-resistant Human Melanoma by Tumor-specific in Vivo Transfer of the Gene Encoding Endothelial Monocyte-activating Polypeptide II Using Recombinant Vaccinia Virus Cancer Res., September 1, 1999; 59(18): 4668 - 4674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. X. Gnant, M. Puhlmann, H. R. Alexander Jr., and D. L. Bartlett Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and Prolongation of Survival in Mice Cancer Res., July 1, 1999; 59(14): 3396 - 3403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.R.J. Evans and S.B. Kaye Vaccine therapy for cancer—fact or fiction? QJM, June 1, 1999; 92(6): 299 - 307. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Morse, Y. Deng, D. Coleman, S. Hull, E. Kitrell-Fisher, S. Nair, J. Schlom, M.-E. Ryback, and H. K. Lyerly A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen Clin. Cancer Res., June 1, 1999; 5(6): 1331 - 1338. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
